INHBE and pulmonary arterial hypertension: In a landmark study published in 2023, Guignabert et al. [95] demonstrated that circulating activins serve as independent prognostic biomarkers in PAH and, importantly, that activin A levels remain largely unchanged despite treatment with mono-, dual- or triple-combination PAH therapies.